Published in final edited form as:

Clin Exp Pharmacol Physiol. 2016 June ; 43(6): 612–615. doi:10.1111/1440-1681.12573.

The initial fall in arterial pressure evoked by endotoxin is mediated by the ventrolateral periaqueductal gray

William R. Millington*, M. Sertac Yilmaz†, and Carlos Feleder*

*Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY

†Department of Medical Pharmacology, Uludag University, Faculty of Medicine, Bursa, Turkey

Abstract

This study tested the hypothesis that the initial fall in arterial pressure evoked by lipopolysaccharide (LPS) is mediated by the ventrolateral column of the midbrain periaqueductal gray region (vPAG). To test this hypothesis, the local anesthetic lidocaine (2%; 0.1 µl, 0.2 µl or 1.0 µl), the delta opioid receptor antagonist naltrindole (2 nmol) or saline was microinjected into the vPAG of isoflurane-anesthetized rats bilaterally and LPS (1 mg/kg) or saline was administered i.v. 2 min later. Both lidocaine and naltrindole inhibited LPS-evoked hypotension significantly but did not affect arterial pressure in saline-treated control animals. Neither lidocaine nor naltrindole altered heart rate significantly in either LPS-treated or control animals. Microinjection of lidocaine or naltrindole into the dorsolateral PAG was ineffective. These data indicate that the vPAG plays an important role in the initiation of endotoxic hypotension and further show that delta opioid receptors in the vPAG participate in the response.

Keywords

Endotoxin; endotoxin shock; lipopolysaccharide; periaqueductal gray; preoptic area; delta receptor; opioid receptor

INTRODUCTION

Lipopolysaccharide (LPS) is commonly used to investigate the hemodynamic effects of gram-negative endotoxemia. Although often assumed to lower arterial pressure by producing vasodilation through a direct action on the vasculature and/or by stimulating cytokine release¹ previous studies from our laboratory indicate that LPS initially lowers arterial pressure through a central mechanism.^{2–4} Specifically, we found that LPS-evoked hypotension could be prevented by microinjecting the local anesthetic lidocaine or the alpha-adrenergic receptor antagonist phentolamine into the hypothalamic preoptic area (POA) of conscious or anesthetized rats.^{2–4} Lipopolysaccharide-evoked hypotension could also be prevented by injecting lidocaine into the nucleus tractus solitarius or by transecting the vagus nerve suggesting that vagus nerve afferents convey the immune signal from

circulating LPS to the brain.³ These findings indicate that endotoxic hypotension is initiated through a central mechanism that involves activation of vagal afferents and stimulation of norepinephrine release in the POA. It remains to be determined how the POA initiates the precipitous fall in arterial pressure in response to LPS.

This study tested the hypothesis that the ventrolateral midbrain periaqueductal gray (vIPAG) region plays an important role in the initiation of endotoxic hypotension. The POA directly innervates the vIPAG as well as other cardioregulatory brain regions.⁵ Electrical stimulation of, or excitatory amino acid injection into, the POA lowers arterial pressure^{6–8} and this response can be prevented by injecting lidocaine or kainic acid into the vIPAG.^{8,9} Destruction of neurons in the nucleus raphe magnus also effectively blocks the depressor response produced by POA stimulation,⁹ consistent with evidence that vIPAG activation lowers arterial pressure by inhibiting sympathetic nerve activity through a descending pathway through the midline raphe nuclei and ventrolateral medulla.^{10–12} Inactivation of the vIPAG also prevents the fall in arterial pressure caused by severe hemorrhage¹³ and visceral nociception.¹⁴ These findings indicate that the vIPAG is a critical component of a descending pathway that lowers arterial pressure as a consequence of trauma, visceral pain and severe blood loss.^{7,10}

There is also evidence that delta opioid receptors in the vIPAG participate in these cardiovascular responses. Microinjection of delta, but not mu or kappa, opioid receptor agonists into the caudal vIPAG lowers arterial pressure¹⁵ and, conversely, microinjection of a delta, but not mu or kappa, receptor antagonist into the vIPAG prevents the fall in arterial pressure caused by severe blood loss or visceral nociception.^{14,16} If the same, or a similar, pathway initiates endotoxic hypotension then blockade of delta receptors in the vIPAG should also inhibit the effects of LPS. The present study thus evaluated whether microinjection of either lidocaine or the delta receptor antagonist naltrindole into the vIPAG inhibits the fall in arterial pressure evoked by LPS.

RESULTS

Lipopolysaccharide (1 mg/kg, i.v.) administration produced a biphasic fall in arterial pressure (Fig. 1A), as shown previously.² Arterial pressure fell abruptly following LPS administration, reaching its nadir within 10 min, then returned toward baseline values within 40 min. A second, more prolonged decline in arterial pressure began after 60 min and arterial pressure remained below baseline for the remainder of the experiment (Fig. 1A).

To test whether the vIPAG participates in LPS-evoked hypotension lidocaine or saline was injected bilaterally into the caudal vIPAG of isoflurane-anesthetized rats and LPS was administered i.v. 2 min later. Lidocaine inhibited the response significantly, attenuating both the initial fall in arterial pressure and the second, decompensatory phase of LPS hypotension (Fig. 1A). Lipopolysaccharide-evoked hypotension was inhibited significantly by both 0.2 µl (Fig. 1A) and 1.0 µl of 2% lidocaine whereas 0.1 µl lidocaine was not significantly inhibitory (data not shown). Lidocaine had no effect on arterial pressure in control animals (Fig. 1A) and neither lidocaine nor LPS altered heart rate significantly (Fig. 1B).

Next, we tested whether delta opioid receptors participate in the response by microinjecting naltrindole (2 nmol) or saline into the vIPAG bilaterally. Naltrindole inhibited LPS hypotension significantly, attenuating both the first and second phases of the response, but did not change arterial pressure in control animals (Fig. 2A). Neither naltrindole nor LPS affected heart rate significantly (data not shown).

In control experiments, microinjection of either lidocaine or naltrindole into the dIPAG failed to inhibit the fall in arterial pressure produced by LPS (Table 1) consistent with previous reports.^{14,16} The hypotension produced by LPS can thus be prevented by inhibiting neuronal activity or by blocking delta receptors in the vIPAG, but not the dIPAG.

DISCUSSION

In this study we show that microinjection of lidocaine or naltrindole into the vIPAG attenuates the fall in arterial pressure evoked by LPS. These experiments were conducted under isoflurane anesthesia although earlier studies showed that anesthesia does not alter baseline blood pressure or heart rate significantly nor does it affect the magnitude or duration of endotoxic hypotension.^{2,16} These findings are predicated on earlier reports that inactivation of the POA inhibits endotoxic hypotension^{2,3} and on anatomical tract-tracing studies showing that the POA densely innervates the vIPAG.⁵ Functional studies also provide evidence that activation of POA neurons lowers arterial pressure through a descending pathway from the POA to the vIPAG and midline raphe nuclei.^{7, 8,11} The current findings thus suggest that the same, or a similar pathway, may be responsible for initiating LPS-evoked hypotension.

The concept that endotoxic hypotension is initiated through a central mechanism is by no means new. In the late 1970's Holaday and Faden¹⁷ reported that i.v. naloxone administration inhibited endotoxic hypotension and subsequently demonstrated that naloxone was equally effective following i.c.v. injection.¹⁸ Delta opioid receptors were later implicated in the response.¹⁹ Accordingly, we found that naltrindole injection into the vIPAG inhibits the fall in arterial pressure caused by severe hemorrhage or visceral nociception.^{14,16}

These findings are consistent with evidence that the vIPAG mediates 'passive' strategies for coping with trauma, predator attack, severe blood loss and deep visceral pain.¹⁰ Activation of the vIPAG produces sympathoinhibition, hypotension, behavioral quiescence and opioid analgesia whereas activation of the dIPAG triggers 'active' coping strategies and causes sympathoexcitation, hypertension, hyperlocomotion and non-opioid analgesia.^{7,10} The present data suggest that the vIPAG also participates in the cardiovascular response to endotoxemia although the rest of the pathway that mediates this response remains to be elucidated.

The central mechanism responsible for hemorrhagic hypotension has been investigated more thoroughly, however. During progressive hemorrhage, arterial pressure is initially maintained by a compensatory increase in sympathetic activity but, if blood loss becomes severe, a second, decompensatory phase ensues in which sympathetic nerve activity is

inhibited and arterial pressure falls.^{20,21} The decompensatory phase of hemorrhage is initiated through a descending pathway from the arcuate nucleus²² that inhibits sympathetic nerve activity through sequential connections to the vIPAG, midline raphe nuclei and ventrolateral medulla.^{10–12} A common descending pathway thus appears to mediate the cardiovascular effects of both hemorrhage and endotoxin.

The hypothesis that endotoxic hypotension is initiated by the same pathway as hemorrhagic hypotension implies that, like hemorrhage, LPS may initially lower arterial pressure by inhibiting sympathetic activity. Indeed, previous work has shown that LPS lowers arterial pressure and produces parallel reductions in splanchnic and renal nerve activities at the same dose (1 mg/kg i.v.) used in our experiments.^{23,24} Lipopolysaccharide increases sympathetic activity at sub-hypotensive doses, however, which presumably maintains arterial pressure by counteracting the peripheral vasodilatory effects of LPS.²⁵ Interestingly, Martelli et al.²⁶ showed that transecting the splanchnic sympathetic nerves of rats treated with a sub-hypotensive dose of LPS (60 µg/kg i.v.) abruptly elevated plasma TNF-α concentrations and lowered arterial pressure. This implies that sub-hypotensive doses of LPS increase sympathetic nerve activity, which suppresses the release of TNF-α and prevents the fall in arterial pressure that would otherwise occur. These findings support the hypothesis that LPS produces a biphasic response; low doses increase sympathetic nerve activity to maintain arterial pressure whereas high doses inhibit sympathetic outflow, allowing arterial pressure to fall.

Nonetheless, other data contradict this simple model. Vaysettes-Courchay et al.²⁷ showed that i.v. infusion of either 1 or 20 mg/kg LPS increased renal sympathetic nerve activity but lowered arterial pressure in anesthetized rats, for example, and Pålsson et al.²⁸ reported that bolus injection of 20 mg/kg endotoxin produced a similar response in conscious animals. This literature is complicated by differences in species, anesthesia and LPS doses and there is an obvious need for a comprehensive study of the relationship between LPS dose, arterial pressure and sympathetic nerve activity.

In conclusion, although the central mechanism that initiates endotoxic hypotension remains to be fully elaborated, the present data indicate that delta opioid receptors in the vIPAG are importantly involved in the response. These data contribute to a growing body of evidence that the vIPAG is a critical component of a descending pathway that integrates the behavioral and autonomic responses to severe blood loss, visceral pain and endotoxemia.

METHODS

Surgical procedures

Male Sprague-Dawley rats (250–300 g; Charles River Laboratories, Wilmington, MA) were anesthetized with 4% isoflurane and maintained with 1.5% isoflurane in 100% O₂. The left femoral artery and left jugular vein were cannulated with PE-50 tubing filled with heparinized saline (100 U/ml), the arterial cannula was connected to a volumetric pressure transducer attached to a DA100C transducer amplifier (BIOPAC Systems, Goleta, CA) and arterial pressure and heart rate were monitored using a Biopac MP150 system. Animal

protocols were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Stereotaxic injections

For intra-vIPAG injections, isoflurane-anesthetized rats were mounted in a stereotaxic frame and lidocaine (2%; 0.1 μ l, 0.2 μ l or 1.0 μ l), naltrindole (2.0 nmol; 0.2 μ l) (Sigma Chemical Co., St. Louis, MO) or an equivalent volume of saline was injected bilaterally into the vIPAG with a Hamilton syringe connected to cannulae lowered vertically 0.8 mm lateral and 8.3 mm caudal from bregma and 6.2 mm below the dural surface.²⁹ For dorsolateral PAG (dIPAG) injections, 2% lidocaine, 0.2 nmol naltrindole or 0.2 μ l saline was injected bilaterally 0.8 mm lateral and 8.3 mm caudal to bregma and 4.6 mm below the dural surface.^{14,16}

Lidocaine and naltrindole were dissolved in saline containing 0.2% Chicago Sky Blue dye to mark the injection sites. Drug doses were selected from dose-response studies published previously.^{13,16} Stereotaxic injections were delivered at a constant rate over a 1 min period and, two minutes later, LPS (1.0 mg/kg) or saline (1 ml/kg) was administered i.v. At the end of each experiment, rats were sacrificed with an overdose of isoflurane, brains were removed, sectioned (50 μ m) and stained with eosin to confirm the location of cannulae. Only data from confirmed cannula placements were included in this report.

Statistical analysis

Data are reported as mean $\pm$ SEM and were analyzed by repeated measure two-way ANOVA followed by Bonferroni's multiple comparison test. A two sided *P* value of <0.05 was considered significant.

Acknowledgments

This research was supported by a grant from NIAID (R15AI072744) to Dr. Feleder. The authors thank Paul Neumann for assistance preparing the manuscript.

References

1. Farias NC, Borelli-Montigny GL, Fauaz G, Feres T, Borges ACR, Paiva TB. Different mechanism of LPS-induced vasodilation in resistance and conductance arteries from SHR and normotensive rats. *Brit J Pharmacol.* 2002; 137:213–20. [PubMed: 12208778]
2. Yilmaz MS, Millington WR, Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by LPS in male rats. *Shock.* 2008; 29:232–37. [PubMed: 18386391]
3. Yilmaz MS, Göktalay G, Millington WR, Myer BS, Cutrera RA, Feleder C. Lipopolysaccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptors in the preoptic anterior hypothalamic area. *J Neuroimmunol.* 2008; 203:39–49. [PubMed: 18653249]
4. Feleder C, Yilmaz MS, Peng J, Göktalay G, Millington WR. The OVLT initiates the fall in arterial pressure evoked by high dose lipopolysaccharide: Evidence that dichotomous, dose-related mechanisms mediate endotoxic hypotension. *J Neuroimmunol.* 2015; 285:94–100. [PubMed: 26198924]

5. Rizvi TA, Ennis M, Shipley MT. Reciprocal connections between the medial preoptic area and the midbrain periaqueductal gray in rat: a WGA-HRP and PHA-L study. *J Comp Neurol.* 1992; 315:1–15. [PubMed: 1371779]
6. Gelsema AJ, Roe MJ, Calaresu FR. Neurally mediated cardiovascular responses to stimulation of cell bodies in the hypothalamus of the rat. *Brain Res.* 1989; 482:67–77. [PubMed: 2706483]
7. Lovick TA. Integrated activity of cardiovascular and pain regulatory systems: role in adaptive behavioural responses. *Prog Neurobiol.* 1993; 40:631–44. [PubMed: 8484005]
8. Behbehani MM, Da Costa Gomez TM. Properties of a projection pathway from the medial preoptic nucleus to the midbrain periaqueductal gray of the rat and its role in the regulation of cardiovascular function. *Brain Res.* 1996; 740:141–50. [PubMed: 8973808]
9. Inui K, Nomura J, Murase S, Nosaka S. Facilitation of the arterial baroreflex by the preoptic area in anaesthetized rats. *J Physiol.* 1995; 488:521–31. [PubMed: 8568691]
10. Bandler R, Keay KA, Floyd N, Price J. Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. *Brain Res Bull.* 2000; 53:95–104. [PubMed: 11033213]
11. Jiang M, Behbehani MM. Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal gray. *Pain.* 2001; 94:139–47. [PubMed: 11690727]
12. Vagg DJ, Bandler R, Keay KA. Hypovolemic shock: Critical involvement of a projection from the ventrolateral periaqueductal gray to the caudal midline medulla. *Neuroscience.* 2008; 152:1099–109. [PubMed: 18343586]
13. Cavun S, Millington WR. Evidence that hemorrhagic hypotension is mediated by the ventrolateral periaqueductal gray region. *Am J Physiol Regul Integr Comp Physiol.* 2001; 281:R747–52. [PubMed: 11506988]
14. Cavun S, Göktaay G, Millington WR. The hypotension evoked by visceral nociception is mediated by delta opioid receptors in the periaqueductal gray. *Brain Res.* 2004; 1019:237–45. [PubMed: 15306258]
15. Keay KA, Crowfoot LJ, Floyd NS, Henderson LA, Christie MJ, Bandler R. Cardiovascular effects of microinjections of opioid agonists into the 'Depressor Region' of the ventrolateral periaqueductal gray region. *Brain Res.* 1997; 762:61–71. [PubMed: 9262159]
16. Cavun S, Resch GE, Rapacon-Baker M, Evec A, Millington WR. Blockade of delta opioid receptors in the ventrolateral periaqueductal gray region inhibits the fall in arterial pressure evoked by hemorrhage. *J Pharmacol Exp Ther.* 2001; 297:612–19. [PubMed: 11303050]
17. Holaday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role for endorphins in shock. *Nature.* 1987; 275:450–51. [PubMed: 357994]
18. Faden AI, Holaday JW. Experimental endotoxin shock: the pathophysiologic function of endorphins and treatment with opiate antagonists. *J Infect Dis.* 1980; 142:229–38. [PubMed: 6251139]
19. Ludbrook L, Ventura S. The decompensatory phase of acute hypovolaemia in rabbits involves a central δ 1-opioid receptor. *Eur J Pharmacol.* 1994; 252:113–16. [PubMed: 8149991]
20. Schadt JC, Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious mammals. *Am J Physiol Heart Circ Physiol.* 1991; 260:H305–18.
21. Evans RG, Ventura S, Dampney RAL, Ludbrook J. Neural mechanisms in the cardiovascular responses to acute central hypovolaemia. *Clin Exp Pharmacol Physiol.* 2001; 28:479–87. [PubMed: 11428384]
22. Göktaay G, Cavun S, Levendusky MC, Resch GE, Veno PA, Millington WR. Hemorrhage activates proopiomelanocortin neurons in the rat hypothalamus. *Brain Res.* 2006; 1070:45–55. [PubMed: 16403465]
23. Koyama S, Manning JW. Role of sympathetic nerve activity in endotoxin induced hypotension in cats. *Cardiovasc Res.* 1985; 19:32–7. [PubMed: 3886138]
24. Koyama S. Central impairment of renal nerve response to stimulation of medullary pressor area in rabbit endotoxic hypotension. *Brain Res.* 1986; 366:217–23. [PubMed: 3516301]

25. MacNeil BJ, Jansen AH, Greenberg AJ, Nance DM. Activation and selectivity of splenic sympathetic nerve electrical activity response to bacterial endotoxin. *Am J Physiol Regul Integr Comp Physiol.* 1996; 270:R264–70.
26. Martelli D, Yao ST, Mancera J, McKinley MJ, McAllen RM. Reflex control of inflammation by the splanchnic anti-inflammatory pathway is sustained and independent of anesthesia. *Am J Physiol Regul Integr Comp Physiol.* 2014; 307:R1085–91. [PubMed: 25163921]
27. Vayssettes-Courchay C, Bouysset F, Verbeuren TJ. Sympathetic activation and tachycardia in lipopolysaccharide treated rats are temporally correlated and unrelated to the baroreflex. *Auton Neurosci Basic Clin.* 2005; 120:35–45.
28. Pålsson J, Ricksten S-E, Delle M, Lundin S. Changes in renal sympathetic nerve activity during experimental septic and endotoxin shock in conscious rats. *Circ Shock.* 1988; 24:133–41. [PubMed: 3286033]
29. Paxinos, G.; Watson, C. *The Rat Brain in Stereotaxic Coordinates.* Academic Press; New York: 2005.

Figure 1. Lidocaine injection into the vPAG prevents the fall in arterial pressure caused by LPS. Lidocaine (2%; 0.2 μ l) or saline was injected bilaterally into the caudal vPAG of isoflurane-anesthetized rats and, 2 min later, LPS (1 mg/kg) or saline was administered i.v. (n=6). Mean arterial pressure (MAP; Panel A) and heart rate (Panel B) were recorded for 180 min. * $P < 0.05$, differs from saline + saline. # $P < 0.05$, differs from saline + LPS.

Figure 2. Blockade of delta opioid receptors in the vIPAG inhibits LPS hypotension. Naltrindole (2 nmol) or saline (0.2 μ l) was injected bilaterally into the caudal vIPAG of isoflurane-anesthetized rats and, 2 min later, LPS (1 mg/kg) or saline was administered i.v. * P <0.05, differs from saline + saline. # P <0.05, differs from saline + LPS.

Table 1

Lidocaine or naltrindole injection into the dIPAG fails to inhibit LPS hypotension.

	<u>Maximum change in MAP (mmHg)</u>	<u>Maximum change in HR (BPM)</u>
Saline + LPS	-31.3 ± 6.7	-27.8 ± 9.1
Lidocaine + LPS	-27.9 ± 4.3	-18.9 ± 7.6
Naltrindole + LPS	-28.7 ± 5.1	-33.9 ± 9.9

Lidocaine (2%), naltrindole (2 nmol) or saline (0.2 μ l) was injected bilaterally into the caudal dIPAG of isoflurane-anesthetized rats and LPS (1 mg/kg) was injected i.v. 2 min later (n = 6). Data represent the maximum change in mean arterial pressure (MAP) or heart rate (HR).